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INTRODUCTION 
Efavirenz is an antiviral medication that prevents human 
immuno deficiency virus (HIV) cells from multiplying in 
our body. Chemically it is (+)6-chloro-4-
cyclopropylethynyl-1,4-dihydro-4(trifluoromethyl)2H-3,1 
benzoxazin- 2- one1. Literature review revealed very few 
analytical methods including RP-HPLC, HPTLC and UV-
spectrophotometry for determination of EFZ in plasma, 
bulk drug and pharmaceutical formulations2-8. In the 
present work, two simple and sensitive spectrophotometric 
methods ( A and B ) have been developed for the 
estimation of EFZ in bulk drug and pharmaceutical dosage 
form. In Method A, EFZ is first diazotized with an 
aqueous solution of nitrous acid followed by coupling 
with β-Naphthol to form an azo derivative9,10 which 
absorbs intensely at 494nm. Method B is First derivative 
spectroscopic method. Spectrophotometric parameters are 
established for standardization of the methods including 
statistical analysis of data.  
EXPERIMENTAL 
Instrument: All spectral and absorbance measurements 
were made on Shimadzu UV-Vis Spectrophotometer-
1650. 
Standard solution of EFZ: A 1mg/ml stock solution of 
EFZ was prepared by dissolving 100mg of drug in 100ml 
of ethanol. 
Sample preparation: 
Twenty tablets were weighed. A quantity equivalent to 
100mg of EFZ  was  weighed  accurately, transferred  to a 
beaker, dissolved in ethanol, filtered through  Whatmann  
filter paper No.1 into a 100ml volumetric flask and made 
up to volume with  ethanol to get a concentration  of 
1mg/ml. 
ASSAY: 
Method A: 
Aliquots of EFZ ranging from 0.25 – 1.5 ml ( 1.0 ml = 
1000 µg) were pipette out into a series of 25ml volumetric 
flasks. To each flask, 1ml of sodium nitrite (0.1M), 2ml of 
hydrochloric acid (2M) and 2ml of β-Naphthol (0.5% w/v) 
were added, mixed thoroughly and made upto volume 
with distilled water. The λmax of the pink coloured 
chromogen was found to be 494nm as shown in Fig.1. The 
absorbance of the pink coloured chromogen was measured 
at 494nm against the reagent blank. The pink chromogen 
was stable for more than 3 hours. The analytical curve was 
constructed by plotting concentration versus absorbance. 
Method B:  
The stock solution was diluted suitably with ethanol to 
give a series of concentration ranging from 4-24µg/ml of 
EFZ. The above solutions were scanned in the range of 
200-400nm and the resultant spectra were derivatised to 
get the first order spectra as shown in Fig.2. The 
amplitude of the corresponding concentrations were 
measured in mm. The calibration curve was constructed 
by plotting amplitude versus concentration. The amount of 
EFZ was computed from the calibration curve. 
Sample Analysis: 
Pharmaceutical formulation of EFZ was successfully 
analysed by the proposed methods. Appropriate aliquots 
were subjected to the above methods and the amount of 
EFZ was determined from the calibration curves.  
RESULTS AND DISCUSSION: 
The optical characteristics such as absorption maxima, 
Beer’s law limits, molar absorptivity and Sandell’s 
sensitivity are furnished in Table-1. The regression 
characteristics like slope(m), intercept(c), correlation co-
efficient(r), percent relative standard deviation(% RSD) 
and standard error(SE) were calculated and the results are 
summarized in Table-1. The results of sample analysis 
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showed that the drug determined by the proposed methods 
was in good agreement with the label claim proving the 
accuracy of the proposed methods. The results of sample 
analysis are furnished in Table-2. 
To study the accuracy and reproducibility of the proposed 
methods, recovery experiments were carried out by adding 
a known amount of drug to preanalysed sample and the 
percentage recovery was calculated.  
 
Figure 1: λmax of pink chromogen of EFZ by Method A 
The results are furnished in Table-2. The results indicate 
that there is no interference of other ingredients present in 
the formulations. Thus, the proposed methods are simple, 
sensitive, economical, accurate and reproducible and 
useful for the routine determination of EFZ in bulk drug 
and its pharmaceutical dosage forms. 
 
Figure 2: First derivative spectrum of EFZ by Method B 
Table 1: Optical and Statistical parameters by Methods A and B 
Parameters Method A Method B 
Absorption maximum/ 
Wavelength range(nm) 
494 200-400 
Linearity Range(µg/ml) 10-60 4-24 
Correlation coefficient(r) 0.999 0.998 
% RSD 0.0001 0.0005 
Standard Error(SE) 0.0424 0.0122 
Regression Equation y=mx+c 0.179x+0.0113 0.0066x+0.1102 
Intercept (c) 0.0113 0.1102 
Slope (m) 0.179 0.0066 
Sandell’s Sensitivity (µg/cm2/0.001A unit) 0.0008 - 
Molar absorptivity (Lmol-1 cm-1) 3.6×103                       - 
 
Table 2: Assay and recovery of EFZ in dosage form 
Method Labelled amount(mg) Amount obtained(mg)* Percentage recovery** 
A 600 600.01 100.1% 
B 600 600.02 99.99% 
*Average of six determinations                         **Average of three determinations 
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